GenoSafe inaugurated its new 1,200 m² laboratories at the Genopole biocluster in Évry-Courcouronnes, designed and equipped in accordance with Good Manufacturing Practices (GMP).
These new facilities strengthen GenoSafe's ability to support its partners throughout the entire development cycle, from the laboratory to commercialization, while ensuring the highest standards for quality control, safety, and efficacy of medicines such as gene and cell therapy drugs, innovative vaccines, and DNA/RNA-based therapies.
Thanks to these laboratories, GenoSafe can provide even more effective support to its partners - biotech companies, the pharmaceutical industry, laboratories, and institutions - in the design, validation, and execution of analytical methods required for the control and release of gene and cell therapy products. The new site also allows GenoSafe to expand its services into a broader range of advanced therapies, including therapeutic vaccines, RNA-based products, monoclonal antibodies, and other innovative therapies. Recruitment will be initiated in 2026 as the facilities become fully operational.
“These new laboratories reflect our ambition to provide a scientific and regulatory environment that meets the highest international standards for advanced therapy products. It marks a new milestone in GenoSafe’s growth and in the development of the French biotherapy ecosystem,” said Serge Braun, President of GenoSafe.